Pharmaceuticals

InMed Pharmaceuticals

InMed Pharmaceuticals released FY2026 Q3 earnings on May 6, 2026 (EST) with actual revenue of USD 0 and EPS of USD -0.7327

InMed Pharmaceuticals released FY2026 9 Months earnings on May 6 (EST), actual revenue USD 1.94 M, actual EPS USD -1.6823

InMed Pharmaceuticals released FY2026 Semi-Annual earnings on February 11 (EST), actual revenue USD 1.94 M, actual EPS USD -0.9495

InMed Pharmaceuticals released FY2026 Q2 earnings on February 11 (EST), actual revenue USD 820.19 K, actual EPS USD -0.5128

InMed Pharmaceuticals released FY2026 Q1 earnings on November 6, 2025 (EST), with actual revenue of USD 1.12 M and EPS of USD -0.4366

InMed Pharmaceuticals Inc. to Hold Annual and Special Shareholders' Meetings on December 17

InMed Pharmaceuticals released FY2025 Q4 earnings on September 23 (EST), actual revenue USD 1.305 M, actual EPS USD -1.1984

InMed Pharmaceuticals released FY2025 earnings on September 23 (EST), actual revenue USD 4.943 M (forecast USD 6.773 M), actual EPS USD -8.3629

InMed Pharmaceuticals Agrees to Stock Sale

InMed Pharmaceuticals Inc. Completes $5 Million Private Placement

InMed Pharmaceuticals Inc. Completes Private Placement Financing for $5 Million

InMed Announces Promising Study Results of Alzheimer's Disease Candidate Drug INM-901

InMed Pharmaceuticals revises standby equity purchase agreement with Yorkville

InMed Pharmaceuticals released FY2025 9 Months Earnings on May 12 (EST), actual revenue USD 2.376 M, actual EPS USD -8.2854

InMed Pharmaceuticals released FY2025 Q3 earnings on May 12 (EST), actual revenue USD 0, actual EPS USD -1.9352

InMed Pharmaceuticals released FY2025 Q2 earnings on February 12, 2025 (EST) with actual revenue of 1.112 M USD and actual EPS of -3.6445 USD

InMed Pharmaceuticals released FY2025 Semi-Annual Earnings on February 12 (EST) with actual revenue of 2.376 M USD and EPS of -6.4335 USD

InMed Pharmaceuticals Inc. Announces New Formulation for Dry Age-Related Macular Degeneration Treatment

InMed Pharmaceuticals released FY2025 Q1 earnings on November 14, 2024 (EST), with actual revenue of 1.265 M USD and EPS of -2.7056

InMed Pharmaceuticals released FY2024 Annual Earnings on September 30, 2024 (EST): Actual Revenue 4.598M USD (Forecast 5.419M USD), Actual EPS -20.1429 (Forecast -16.0586)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AMIX

MTVA

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

benzinga_article

Autonomix Medical

WORK Medical Tech

Edesa Biotech

Co-Diagnostics

AIM ImmunoTech

iShares US Medical Devices

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

LABU

SBIO

ARKG

/C O R R E C T I O N -- InMed Pharmaceuticals/ | INM Stock News

StockTitan

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

/C O R R E C T I O N -- InMed Pharmaceuticals/ | INM Stock News

InMed Pharmaceuticals Inc. has amended its agreement with Armistice Capital Master Fund Ltd. regarding preferred investment options. The exercise price for purchasing common shares has been reduced from $16.60 to $0.80. The options were part of a private placement under the Securities Act. There is no guarantee that the options will be exercised.

VG Health

InMed Pharmaceuticals Amends Preferred Investment Options | INM Stock News

InMed Pharmaceuticals(INM.US)

12 Health Care Stocks Moving In Tuesday's Intraday Session

/C O R R E C T I O N -- InMed Pharmaceuticals/ | INM Stock News

InMed Pharmaceuticals Amends Preferred Investment Options | INM Stock News